Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Authors
Chen, YaoyuPeng, Cong
Abraham, Sheela A.
Shan, Yi
Guo, Zhiru
Desouza, Ngoc
Cheloni, Giulia
Li, Dongguang
Holyoake, Tessa L.
Li, Shaoguang
UMass Chan Affiliations
Department of Medicine, Division of Hematology OncologyDocument Type
Journal ArticlePublication Date
2014-09-01Keywords
AnimalsApoptosis
Arachidonate 15-Lipoxygenase
Cell Line, Tumor
Cells, Cultured
Fluorenes
Fusion Proteins, bcr-abl
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Lipoxygenase Inhibitors
Mice
Mice, Inbred C57BL
Neoplastic Stem Cells
P-Selectin
Cancer Biology
Hematology
Hemic and Lymphatic Diseases
Neoplasms
Oncology
Metadata
Show full item recordAbstract
Cancer stem cells (CSCs) are responsible for the initiation and maintenance of some types of cancer, suggesting that inhibition of these cells may limit disease progression and relapse. Unfortunately, few CSC-specific genes have been identified. Here, we determined that the gene encoding arachidonate 15-lipoxygenase (Alox15/15-LO) is essential for the survival of leukemia stem cells (LSCs) in a murine model of BCR-ABL-induced chronic myeloid leukemia (CML). In the absence of Alox15, BCR-ABL was unable to induce CML in mice. Furthermore, Alox15 deletion impaired LSC function by affecting cell division and apoptosis, leading to an eventual depletion of LSCs. Moreover, chemical inhibition of 15-LO function impaired LSC function and attenuated CML in mice. The defective CML phenotype in Alox15-deficient animals was rescued by depleting the gene encoding P-selectin, which is upregulated in Alox15-deficient animals. Both deletion and overexpression of P-selectin affected the survival of LSCs. In human CML cell lines and CD34+ cells, knockdown of Alox15 or inhibition of 15-LO dramatically reduced survival. Loss of Alox15 altered expression of PTEN, PI3K/AKT, and the transcription factor ICSBP, which are known mediators of cancer pathogenesis. These results suggest that ALOX15 has potential as a therapeutic target for eradicating LSCs in CML.Source
J Clin Invest. 2014 Sep;124(9):3847-62. doi: 10.1172/JCI66129. Epub 2014 Aug 8. Link to article on publisher's siteDOI
10.1172/JCI66129Permanent Link to this Item
http://hdl.handle.net/20.500.14038/34788PubMed ID
25105362Related Resources
Link to Article in PubMedRights
Publisher PDF posted as allowed by the publisher's author rights policy at http://content-assets.jci.org/admin/forms/jcicopyright.pdf.
ae974a485f413a2113503eed53cd6c53
10.1172/JCI66129